BMY ▲ +0.2% - Bristol-Myers Squibb Company $BMY Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3... 08-OCT-2026 06:59 AM ET